Group 1 - On November 14, Baike Bio's stock rose by 1.93%, with a trading volume of 235 million yuan [1] - The financing data shows that on the same day, Baike Bio had a financing purchase amount of 41.97 million yuan and a net financing purchase of 10.47 million yuan [1] - As of November 14, the total balance of margin trading for Baike Bio was 237 million yuan, with the financing balance accounting for 2.40% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, Baike Bio had 10,800 shareholders, an increase of 7.23% from the previous period, while the average circulating shares per person decreased by 6.74% to 38,216 shares [2] - For the period from January to September 2025, Baike Bio reported an operating income of 474 million yuan, a year-on-year decrease of 53.76%, and a net profit attributable to shareholders of -158 million yuan, a decrease of 164.76% [2] - Since its A-share listing, Baike Bio has distributed a total of 235 million yuan in dividends, with 194 million yuan distributed over the past three years [2]

Core Viewpoint - The company has no plans for acquisition and is focused on its long-term development while enhancing its core competitiveness in the vaccine sector [2] Group 1: Company Strategy - The company emphasizes high-quality development and is actively advancing its research, production, and sales efforts [2] - The company is committed to improving its product pipeline, particularly in adult vaccines, multi-valent vaccines, and mRNA vaccines [2] Group 2: Market Environment - The company acknowledges the opportunities and challenges presented by an aging population and the emergence of new technologies and products [2] - The company aims to enhance its investment value and shareholder return capabilities based on quality improvement [2]

证券代码：688276 证券简称：百克生物 公告编号：2025-044 长春百克生物科技股份公司 关于选举第六届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司章程指引 （2025 年修订）》等法律法规、规范性文件及《长春百克生物科技股份公司章 程》（以下简称"《公司章程》"）《长春百克生物科技股份公司董事会议事规 则》的相关规定，长春百克生物科技股份公司（以下简称"公司"）董事会设职 工代表董事一名。公司于 2025 年 11 月 14 日召开职工代表大会，会议的召开及 表决程序符合职工代表大会决策的有关规定，经民主讨论、表决，全体职工代表 一致审议通过了《关于选举第六届董事会职工代表董事的议案》，同意选举佟雪 莲女士（简历详见附件）为公司第六届董事会职工代表董事，任期自本次职工代 表大会审议通过之日起至公司第六届董事会任期届满之日止。 佟雪莲女士符合《公司法》《公 ...

（文章来源：证券日报） 证券日报网讯 11月14日晚间，百克生物发布公告称，公司于2025年11月14日召开职工代表大会审议通 过了《关于选举第六届董事会职工代表董事的议案》，同意选举佟雪莲女士为公司第六届董事会职工代 表董事，任期自本次职工代表大会审议通过之日起至公司第六届董事会任期届满之日止。 ...

Market Overview - The biopharmaceutical sector increased by 0.3% on November 14, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3990.49, down by 0.97%, while the Shenzhen Component Index closed at 13216.03, down by 1.93% [1] Stock Performance - Jindike (688670) closed at 28.03, up by 19.99% with a trading volume of 105,500 shares and a transaction value of 270 million [1] - Hualan Ting (301207) closed at 25.38, up by 7.22% with a trading volume of 336,800 shares [1] - Other notable performers include: - Saikai Pharmaceutical (300485) at 13.35, up by 4.54% [1] - Olin Bio (616889) at 24.81, up by 4.29% [1] - Wowo Bio (300357) at 33.65, up by 3.03% [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 59.84 million from institutional investors, while retail investors saw a net inflow of 23.85 million [2][3] - Key stocks with significant capital flow include: - Ganli Pharmaceutical (603087) with a net inflow of 62.98 million from institutional investors [3] - Jindike (688670) with a net inflow of 40.32 million from institutional investors [3] - Hualan Ting (301207) with a net inflow of 27.99 million from institutional investors [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公司章程指引 （2025 年修订）》等法律法规、规范性文件及《长春百克生物科技股份公司章 程》（以下简称"《公司章程》"）《长春百克生物科技股份公司董事会议事规 则》的相关规定，长春百克生物科技股份公司（以下简称"公司"）董事会设职 工代表董事一名。公司于 2025 年 11 月 14 日召开职工代表大会，会议的召开及 表决程序符合职工代表大会决策的有关规定，经民主讨论、表决，全体职工代表 一致审议通过了《关于选举第六届董事会职工代表董事的议案》，同意选举佟雪 莲女士（简历详见附件）为公司第六届董事会职工代表董事，任期自本次职工代 表大会审议通过之日起至公司第六届董事会任期届满之日止。 佟雪莲女士符合《公司法》《公司章程》规定的任职资格和条件，不存在不 得担任公司董事的情形，亦未被中国证监会采取证券市场禁入措施或被证券交易 所认定为不适当人选。 本次 ...

Core Points - Changchun High-tech announced that its subsidiary, Changchun Baike Biotechnology Co., has received the clinical trial approval notice from the National Medical Products Administration for its adsorbed acellular combined vaccine for adults and adolescents [1] Group 1 - The company has made significant progress in vaccine development with the approval of a clinical trial for a new vaccine [1]

Core Viewpoint - The company, Baike Bio, has received approval from the National Medical Products Administration for its clinical trial of the Adsorbed Acellular Bivalent Pertussis Vaccine for adults and adolescents [2] Group 1 - The approval notification for the clinical trial was issued on November 12 [2] - The vaccine is intended for use in both adults and adolescents [2]

格隆汇11月12日｜长春高新(000661.SZ)公告称，公司子公司百克生物收到国家药品监督管理局对其吸 附无细胞百(二组分)白破联合疫苗(成人及青少年用)的《药物临床试验批准通知书》。该疫苗是一种可 以同时预防青少年及成人百日咳、白喉、破伤风的疫苗，接种对象为10周岁及以上人群。若该疫苗顺利 完成临床试验并获批上市，将进一步完善公司疫苗研发管线，丰富公司联合疫苗产品矩阵，有助于公司 优化产品结构和主营业务的全面发展。 ...

Core Viewpoint - Changchun High-tech's subsidiary, Baike Bio, has received approval for clinical trials of an acellular combined vaccine for adolescents and adults, which aims to prevent whooping cough, diphtheria, and tetanus [1] Group 1 - The vaccine is intended for individuals aged 10 years and older [1] - Successful completion of clinical trials and subsequent approval for market launch will enhance the company's vaccine research pipeline [1] - This development will enrich the company's portfolio of combined vaccines, aiding in optimizing product structure and overall business growth [1]